



# Financial Tear Sheet

## Corporate Profile

Histogenics is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics' lead investigational product, NeoCart, is designed to rebuild a patient's own knee cartilage to treat pain at the source and potentially prevent a patient's progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics' technology platform has the potential to be used for a broad range of additional restorative cell therapy indications.

## Primary IR Contact

Elissa S. Cote  
Vice President, Marketing and External Relations  
Histogenics Corporation  
**Phone:** 781.547.7900  
**E-mail:** [InvestorRelations@histogenics.com](mailto:InvestorRelations@histogenics.com)

## Stock Performance

### HSGX (COMMON STOCK)

<b>Exchange</b>	NASDAQ (US Dollar)
<b>Price</b>	<b>\$2.44</b>
<b>Change (%)</b>	<b>▼ 0.02 (0.81%)</b>
<b>Volume</b>	99,219
<b>52 Week Low</b>	\$1.60
<b>Market Cap</b>	\$69,997,285
<b>Rolling EPS</b>	-1.24
<b>PE Ratio</b>	N/A
<b>Shares Outstanding</b>	28,687,412

Data as of 07/17/18 4:00 p.m. ET



## Recent Headlines & Events

05/31/18 - 8:31 a.m.

[Histogenics Corporation to Host Investor Day on June 19, 2018](#)

05/10/18 - 6:30 a.m.

[Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results](#)

04/26/18 - 8:30 a.m.

[Histogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018](#)

There are currently no events scheduled.

## SEC Filings

FILING DATE	FORM
06/19/18	4
06/19/18	4
06/19/18	4
06/19/18	4

## Corporate Governance

[Garheng Kong, M.D., Ph.D.](#) Chairman – Founder and Managing Partner of HealthQuest Capital

[Josh Baltzell](#) Managing Director, Split Rock Partners

[David Gill](#) Chairman, Audit Committee

[Adam Gridley](#) President and Chief Executive Officer

[John Johnson](#) Independent Member

[Michael Lewis](#) Chairman of Oceana Investment Partners LLP

[Kevin Rakin](#) Independent Member

[Susan Washer](#) President and Chief Executive Officer of AGTC

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Data provided by Nasdaq. Minimum 15 minutes delayed. [View Attributions and Sources](#)